Author

Fernando Bermejo

EFFICACY AND SAFETY OF RE-INDUCTION WITH INTRAVENOUS USTEKINUMAB IN PATIENTS WITH CROHN´S DISEASE AND LOSS OF RESPONSE TO THAT DRUG
EFFICACY AND SAFETY OF RE-INDUCTION WITH INTRAVENOUS USTEKINUMAB IN PATIENTS WITH CROHN´S DISEASE AND LOSS OF RESPONSE TO THAT DRUG

Fernando Bermejo  et al.

INCIDENCE, CLINICAL PRESENTATION, AND SEVERITY OF SARS-COV-2 INFECTION IN INFLAMMATORY BOWEL DISEASE PATIENTS IN THE “SECOND AND THE THIRD WAVE” OF INFECTION
INCIDENCE, CLINICAL PRESENTATION, AND SEVERITY OF SARS-COV-2 INFECTION IN INFLAMMATORY BOWEL DISEASE PATIENTS IN THE “SECOND AND THE THIRD WAVE” OF INFECTION

Fernando Bermejo  et al.

MICROBIOME CHARACTERIZATION IN STOOL FROM NEWLY DIAGNOSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE
MICROBIOME CHARACTERIZATION IN STOOL FROM NEWLY DIAGNOSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Fernando Bermejo  et al.

EFFECTIVENESS AND SAFETY OF USTEKINUMAB (UST) IN PATIENTS WITH ACTIVE CROHN'S DISEASE (CD) IN REAL LIFE: SUSTAIN STUDY
EFFECTIVENESS AND SAFETY OF USTEKINUMAB (UST) IN PATIENTS WITH ACTIVE CROHN'S DISEASE (CD) IN REAL LIFE: SUSTAIN STUDY

Fernando Bermejo  et al.

PROTEOMIC PROFILE OF SERUM AND URINE IN NEWLY DIAGNOSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE: NEW APPROACH FOR BIOMARKER DISCOVERY
PROTEOMIC PROFILE OF SERUM AND URINE IN NEWLY DIAGNOSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE: NEW APPROACH FOR BIOMARKER DISCOVERY

Fernando Bermejo  et al.

LONG-TERM DURABILITY AND SAFETY OF USTEKINUMAB (UST) IN PATIENTS WITH ACTIVE CROHN'S DISEASE (CD) IN REAL LIFE: SUSTAIN STUDY
LONG-TERM DURABILITY AND SAFETY OF USTEKINUMAB (UST) IN PATIENTS WITH ACTIVE CROHN'S DISEASE (CD) IN REAL LIFE: SUSTAIN STUDY

Fernando Bermejo  et al.

IDENTIFICATION OF URINE AND SERUM DIAGNOSTIC BIOMARKERS OF INFLAMMATORY BOWEL DISEASE USING A PROTEOMIC APPROACH
IDENTIFICATION OF URINE AND SERUM DIAGNOSTIC BIOMARKERS OF INFLAMMATORY BOWEL DISEASE USING A PROTEOMIC APPROACH

Fernando Bermejo  et al.

ANALYSIS OF INTESTINAL TISSUE FROM NEWLY DIAGNOSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE REVEALS DISTINCT PROTEOMIC PROFILES
ANALYSIS OF INTESTINAL TISSUE FROM NEWLY DIAGNOSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE REVEALS DISTINCT PROTEOMIC PROFILES

Fernando Bermejo  et al.

EFFECTIVENESS AND SAFETY OF USTEKINUMAB IN ULCERATIVE COLITIS: REAL WORLD EVIDENCE FROM ENEIDA REGISTRY
EFFECTIVENESS AND SAFETY OF USTEKINUMAB IN ULCERATIVE COLITIS: REAL WORLD EVIDENCE FROM ENEIDA REGISTRY

Fernando Bermejo  et al.

EFFECTIVENESS OF SECOND-LINE HELICOBACTER PYLORI ERADICATION TREATMENTS IN SPAIN: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
EFFECTIVENESS OF SECOND-LINE HELICOBACTER PYLORI ERADICATION TREATMENTS IN SPAIN: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Fernando Bermejo  et al.

ACCELERATED OR ESCALATED INDUCTION REGIMENS OF INFLIXIMAB FOR STEROID-REFRACTORY ACUTE SEVERE ULCERATIVE COLITIS IN CLINICAL PRACTICE: DATA FORM THE ENEIDA REGISTRY
ACCELERATED OR ESCALATED INDUCTION REGIMENS OF INFLIXIMAB FOR STEROID-REFRACTORY ACUTE SEVERE ULCERATIVE COLITIS IN CLINICAL PRACTICE: DATA FORM THE ENEIDA REGISTRY

Fernando Bermejo  et al.

EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB AND USTEKINUMAB THERAPY FOR COMPLEX PERIANAL FISTULA IN CROHN’S DISEASE: THE HEAL STUDY
EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB AND USTEKINUMAB THERAPY FOR COMPLEX PERIANAL FISTULA IN CROHN’S DISEASE: THE HEAL STUDY

Fernando Bermejo  et al.

PROTEOMIC CHARACTERIZATION OF SERUM EXTRACELLULAR VESICLES FROM NEWLY DIAGNOSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE
PROTEOMIC CHARACTERIZATION OF SERUM EXTRACELLULAR VESICLES FROM NEWLY DIAGNOSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Fernando Bermejo  et al.

REAL WORLD EVIDENCE OF TOFACINITIB IN ULCERATIVE COLITIS: SHORT AND LONG-TERM EFFECTIVENESS, SAFETY AND IMPACT OF EXTRAINTESTINAL MANIFESTATIONS AND IMMUNOMEDIATED DISEASES
REAL WORLD EVIDENCE OF TOFACINITIB IN ULCERATIVE COLITIS: SHORT AND LONG-TERM EFFECTIVENESS, SAFETY AND IMPACT OF EXTRAINTESTINAL MANIFESTATIONS AND IMMUNOMEDIATED DISEASES

Fernando Bermejo  et al.

TOFACITINIB IN ULCERATIVE COLITIS: REAL WORLD EVIDENCE FROM ENEIDA REGISTRY
TOFACITINIB IN ULCERATIVE COLITIS: REAL WORLD EVIDENCE FROM ENEIDA REGISTRY

Fernando Bermejo  et al.

PERFORMANCE OF SCREENING STRATEGIES FOR LATENT TUBERCULOSIS INFECTION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: RESULTS FROM THE ENEIDA REGISTRY OF GETECCU
PERFORMANCE OF SCREENING STRATEGIES FOR LATENT TUBERCULOSIS INFECTION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: RESULTS FROM THE ENEIDA REGISTRY OF GETECCU

Fernando Bermejo  et al.

LONG-TERM EVOLUTION AFTER ANTI-TNF DRUG DISCONTINUATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
LONG-TERM EVOLUTION AFTER ANTI-TNF DRUG DISCONTINUATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Fernando Bermejo  et al.

INFLAMMATORY BOWEL DISEASE IN IMMIGRANTS TO SPAIN: RESULTS OF THE EIIMIGRA STUDY FROM GETECCU (ENEIDA REGISTRY)
INFLAMMATORY BOWEL DISEASE IN IMMIGRANTS TO SPAIN: RESULTS OF THE EIIMIGRA STUDY FROM GETECCU (ENEIDA REGISTRY)

Fernando Bermejo  et al.

LONG-TERM TRENDS IN TARGETED THERAPIES USAGE IN INFLAMMATORY BOWEL DISEASE: TRENDY STUDY OF ENEIDA
LONG-TERM TRENDS IN TARGETED THERAPIES USAGE IN INFLAMMATORY BOWEL DISEASE: TRENDY STUDY OF ENEIDA

Fernando Bermejo  et al.

EXPERIENCE WITH SINGLE-CAPSULE BISMUTH QUADRUPLE THERAPY IN 8,000 PATIENTS FROM THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG)
EXPERIENCE WITH SINGLE-CAPSULE BISMUTH QUADRUPLE THERAPY IN 8,000 PATIENTS FROM THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG)

Fernando Bermejo  et al.

Item 1 - 20 / 23
1
2